US 12,285,404 B2
Prevention of rosacea inflammation
Richard L. Gallo, San Diego, CA (US); Anna Di Nardo, La Jolla, CA (US); and Yumiko Muto, La Jolla, CA (US)
Assigned to The Regents of the University of California, Oakland, CA (US)
Filed by The Regents of the University of California, Oakland, CA (US)
Filed on Jun. 7, 2022, as Appl. No. 17/834,626.
Application 16/576,730 is a division of application No. 15/726,069, filed on Oct. 5, 2017, abandoned.
Application 15/726,069 is a division of application No. 14/774,892, granted, now 9,801,848, issued on Oct. 31, 2017, previously published as PCT/US2014/025069, filed on Mar. 12, 2014.
Application 17/834,626 is a continuation of application No. 16/576,730, filed on Sep. 19, 2019, granted, now 11,382,890.
Claims priority of provisional application 61/780,758, filed on Mar. 13, 2013.
Prior Publication US 2023/0181518 A1, Jun. 15, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/352 (2006.01); A61K 9/00 (2006.01); A61K 31/277 (2006.01); A61K 31/4741 (2006.01); A61K 31/519 (2006.01); A61K 45/06 (2006.01)
CPC A61K 31/352 (2013.01) [A61K 9/0014 (2013.01); A61K 31/277 (2013.01); A61K 31/4741 (2013.01); A61K 31/519 (2013.01); A61K 45/06 (2013.01)] 9 Claims
 
1. A composition, comprising:
a mast cell stabilizer selected from the group consisting of lodoxamide, nedocromil, cromolyn, pemirolast, pharmaceutical salts thereof, and any combination thereof;
a serine protease inhibitor selected from the group consisting of Cystatin, aprotinin, 4-(2-aminoethyl)-benzenesulfonylfluoride, aminocaproic acid, kunitz-type protease inhibitor, amyloid beta protein precursor, TFPI (Tissue Factor Pathway Inhibitor), collagen alpha 3, collagen alpha 3 (VI) chain precursor, HKIB9 (Human Kunitz-type Inhibitor type 9), ITI-KD1 (Inter-Trypsin Inhibitor, Kunitz Domain 1), ITI-KD2 (Inter-Trypsin Inhibitor, Kunitz Domain 2), Beta-1-Bungarotoxin B chain, snake venom protease inhibitors, and any combination thereof; and
an agent that inhibits a neuropeptide selected from the group consisting of substance P (SP), calcitonin gene-related peptide (CGRP), vasoactive intestinal peptide (VIP), neurokinin A (NKA), pituitary adenylate cyclase-activating peptide (PACAP), and any combination thereof.